These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 39389734)

  • 1. Right Ventricular Dysfunction in Patients Undergoing High-Risk PCI with Impella.
    Rommel KP; Bonnet G; Bellumkonda L; Lansky AJ; Zhao D; Thompson JB; Zhang Y; Redfors B; Lurz PC; Granada JF; Bharadwaj AS; Basir MB; O'Neill WW; Burkhoff D
    J Card Fail; 2024 Oct; 30(10):1244-1254. PubMed ID: 39389734
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical outcomes among patients with mitral valve regurgitation undergoing Impella-supported high-risk PCI.
    Abu-Much A; Grines CL; Chen S; Batchelor WB; Zhao D; Falah B; Maini AS; Redfors B; Bellumkonda L; Bharadwaj AS; Moses JW; Truesdell AG; Zhang Y; Zhou Z; Baron SJ; Lansky AJ; Basir MB; O'Neill WW; Cohen DJ
    Int J Cardiol; 2024 Dec; 417():132555. PubMed ID: 39270940
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Sex Differences in pLVAD-Assisted High-Risk Percutaneous Coronary Intervention: Insights From the PROTECT III Study.
    Shah T; Abu-Much A; Batchelor WB; Grines CL; Baron SJ; Zhou Z; Li Y; Maini AS; Redfors B; Hussain Y; Wollmuth JR; Basir MB; O'Neill WW; Lansky AJ
    JACC Cardiovasc Interv; 2023 Jul; 16(14):1721-1729. PubMed ID: 37409991
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Angiographic Characteristics and Clinical Outcomes in Patients With Chronic Kidney Disease Undergoing Impella-Supported High-Risk Percutaneous Coronary Intervention: Insights From the cVAD PROTECT III Study.
    Bharadwaj AS; Abu-Much A; Maini AS; Zhou Z; Li Y; Batchelor WB; Grines CL; Baron SJ; Redfors B; Lansky AJ; Basir MB; O'Neill WW
    Circ Cardiovasc Interv; 2024 Jul; 17(7):e013503. PubMed ID: 38708609
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Right ventricular function in heart failure with preserved ejection fraction: a community-based study.
    Mohammed SF; Hussain I; AbouEzzeddine OF; Takahama H; Kwon SH; Forfia P; Roger VL; Redfield MM
    Circulation; 2014 Dec; 130(25):2310-20. PubMed ID: 25391518
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Multiparametric right ventricular assessment improves risk stratification in patients with new-onset acute heart failure.
    Astengo M; Bobbio E; Polte CL; Täll E; Bollano E; Bech-Hanssen O
    ESC Heart Fail; 2024 Oct; 11(5):3378-3387. PubMed ID: 38967241
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Implications of anemia in patients undergoing PCI with Impella-support: insights from the PROTECT III study.
    Falah B; Redfors B; Zhao D; Bharadwaj AS; Basir MB; Thompson JB; Patel RAG; Schonning MJ; Abu-Much A; Zhang Y; Batchelor WB; Grines CL; O'Neill WW
    Front Cardiovasc Med; 2024; 11():1429900. PubMed ID: 39091353
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Unprotected versus protected high-risk percutaneous coronary intervention with the Impella 2.5 in patients with multivessel disease and severely reduced left ventricular function.
    Becher T; Eder F; Baumann S; Loßnitzer D; Pollmann B; Behnes M; Borggrefe M; Akin I
    Medicine (Baltimore); 2018 Oct; 97(43):e12665. PubMed ID: 30412063
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Nonemergent Percutaneous Coronary Intervention on an Unprotected Left Main Coronary Artery Supported with Impella® Heart Pump in Patients Ineligible for Surgical Revascularization.
    Meraj PM; Dixon S; Moses J; Ibrahim K; Schäfer A; Akin I; Hill J; Schreiber T; O'Neill WW
    J Interv Cardiol; 2019; 2019():9691753. PubMed ID: 31772553
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Influence of left ventricular ejection fraction in patients undergoing contemporary pLVAD-supported high-risk PCI.
    Abu-Much A; Grines CL; Batchelor WB; Maini AS; Zhang Y; Redfors B; Bellumkonda L; Bharadwaj AS; Moses JW; Truesdell AG; Li Y; Baron SJ; Lansky AJ; Basir MB; Cohen DJ; O'Neill WW
    Am Heart J; 2024 Mar; 269():139-148. PubMed ID: 38151142
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Impact of hemodynamic support with Impella 2.5 versus intra-aortic balloon pump on prognostically important clinical outcomes in patients undergoing high-risk percutaneous coronary intervention (from the PROTECT II randomized trial).
    Dangas GD; Kini AS; Sharma SK; Henriques JP; Claessen BE; Dixon SR; Massaro JM; Palacios I; Popma JJ; Ohman M; Stone GW; O'Neill WW
    Am J Cardiol; 2014 Jan; 113(2):222-8. PubMed ID: 24527505
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Feasibility and efficacy of the 2.5 L and 3.8 L impella percutaneous left ventricular support device during high-risk, percutaneous coronary intervention in patients with severe aortic stenosis.
    Spiro J; Venugopal V; Raja Y; Ludman PF; Townend JN; Doshi SN
    Catheter Cardiovasc Interv; 2015 May; 85(6):981-9. PubMed ID: 24408882
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Acute Biventricular Mechanical Circulatory Support for Cardiogenic Shock.
    Kuchibhotla S; Esposito ML; Breton C; Pedicini R; Mullin A; O'Kelly R; Anderson M; Morris DL; Batsides G; Ramzy D; Grise M; Pham DT; Kapur NK
    J Am Heart Assoc; 2017 Oct; 6(10):. PubMed ID: 29054842
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Impact of right heart function on outcome in patients with functional mitral regurgitation and chronic heart failure undergoing percutaneous edge-to-edge-repair.
    Osteresch R; Diehl K; Kühl M; Fiehn E; Schmucker J; Backhaus T; Fach A; Wienbergen H; Hambrecht R
    J Interv Cardiol; 2018 Dec; 31(6):916-924. PubMed ID: 30397932
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Six months follow-up of protected high-risk percutaneous coronary intervention with the microaxial Impella pump: results from the German Impella registry.
    Baumann S; Werner N; Al-Rashid F; Schäfer A; Bauer T; Sotoudeh R; Bojara W; Shamekhi J; Sinning JM; Becher T; Eder F; Akin I
    Coron Artery Dis; 2020 May; 31(3):237-242. PubMed ID: 31658135
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Neutrophil/lymphocyte ratio is associated with right ventricular dysfunction in patients with acute inferior ST-segment elevation myocardial infarction.
    Yaylak B; Ede H; Baysal E; Altıntas B; Akyuz S; Sevuk U; Erdoğan G; Comert N; Cakmak EO; Altındag R; Karahan Z; Bilge O; Cevik K
    Cardiol J; 2016; 23(1):100-6. PubMed ID: 26412608
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Outcomes of bailout percutaneous ventricular assist device versus prophylactic strategy in patients undergoing nonemergent percutaneous coronary intervention.
    O'Neill BP; Grines C; Moses JW; Ohman EM; Lansky A; Popma J; Kapur NK; Schreiber T; Mannino S; O'Neill WW; Medjamia AM; Mahmud E
    Catheter Cardiovasc Interv; 2021 Oct; 98(4):E501-E512. PubMed ID: 34051033
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prognostic Value of Right Ventricular Dysfunction on Clinical Outcomes After Transcatheter Aortic Valve Replacement.
    Asami M; Stortecky S; Praz F; Lanz J; Räber L; Franzone A; Piccolo R; Siontis GCM; Heg D; Valgimigli M; Wenaweser P; Roost E; Windecker S; Pilgrim T
    JACC Cardiovasc Imaging; 2019 Apr; 12(4):577-587. PubMed ID: 29454762
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Gender difference with the use of percutaneous left ventricular assist device in patients undergoing complex high-risk percutaneous coronary intervention: From pVAD Working Group.
    Doshi R; Singh A; Jauhar R; Meraj PM
    Eur Heart J Acute Cardiovasc Care; 2019 Jun; 8(4):369-378. PubMed ID: 29308660
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Incidence, Predictive Factors, and Prognostic Impact of Right Ventricular Dysfunction Before Transcatheter Aortic Valve Implantation.
    Durand E; Sacri C; Levesque T; Tron C; Barbe T; Hemery T; Burdeau J; Dacher JN; Eltchaninoff H
    Am J Cardiol; 2021 Dec; 161():63-69. PubMed ID: 34794620
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.